The global E3 ubiquitin protein ligase XIAP market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Ubiquitin ligase is also called as E3 ubiquitin ligase. It is a protein that staffs an E2 ubiquitin-conjugating enzyme that has been loaded with ubiquitin and recognizes a protein substrate while assisting or directly catalyzing the transfer of ubiquitin from the E2 to the protein substrate. The major factor for the growth of the market is the increasing prevalence of cancer across the globe. 

According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. In men, prostate, lung, and colorectal cancers will account for an estimated 43% of all cancers diagnosed while for women, the three most common cancers are breast, lung, and colorectal which will account for an estimated 50% of all new cancer diagnoses in women in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the rising prevalence of cancer is driving the growth of the market as E3 ubiquitin protein ligase XIAP plays a crucial role in protein function and regulation. 

Some major key players in the market include Novartis International AG, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. In addition, funding opportunity has been witnessed, which in turn, is expected to drive the market growth during the forecast period. For instance, in June 2021, Stablix Therapeutics announced a $63 million Series A financing which was led by founding investor Versant Ventures with NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities. Stablix is a biotechnology company that pioneers in the field of Targeted Protein Stabilization (TPS). 

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- Novartis International AG, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Ltd., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global E3 Ubiquitin Protein Ligase XIAP Market Report by Segment

By Type 

    • ASTX-660

    • FL-118

    • AD-O53.2

    • LCL-161

    • SM-1200

    • Others

By Application 

    • Solid Tumor

    • Fallopian Tube Cancer

    • Lung Cancer

    • Peritoneal Cancer

    • Others

Global E3 Ubiquitin Protein Ligase XIAP Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa